19 / 50
Background of Netupitant and “NEPA”
• NEPA is a fixed-dose combination of oral netupitant and oral palonosetron. It is designed to
improve antiemetic control by:
– Administration as an all oral combination agent
– A single dose schedule given on the day of chemotherapy only
• Palonosetron is a widely used 5-HT
3
RA with: a long plasma half-life, demonstrated activity both
orally and IV, and an good safety profile
– Palonosetron is specifically recommended in key antiemetic settings in major evidence-based guidelines
– Palonosetron does not prolong QTc intervals
• Netupitant is a new NK
1
RA with a long plasma half-life and a long duration of receptor
occupancy